An independent jury of experts annually selects the laureates of the Swiss Biotech Success Stories.
Undergrad at ETH in Zürich with Master in Immunology. PhD at the Biocenter in Basel in biochemistry, and then Member of the Basel institute for immunology. Followed by Hoffmann-La Roche Ltd as a Global discovery portfolio manager. Further as Fundamental analyst at BT&T asset management, and as a freelance consultant. Established Biopolo Ticino where he also participated in the creation of the Swiss marketing platforms Swiss Biotech and Swiss Medtech. Then Director Business Development at Actelion, and NovImmune.
MD (1980) and a Neuroscientist (1983) at the Universities of Geneva and Fribourg in Switzerland. Faculty positions at Brown University and the University of Lausanne prior to joining EPFL.He has received numerous honors, including the Robert Bing Prize of the Swiss Academy of Medicine and the Pfizer Foundation Prize for Clinical Neurosciences. He is a member of the scientific committee of the Italian Institute of Technology and a member of the Singapore Biomedical Sciences International Advisory Council. Prof. Aebischer is a member of the Board of Lonza, Nestlé and Logitech and a founder of three biotech companies. He chairs the Novartis Venture Fund and is a Senior Partner of NanoDimension-III.
Stefanie Flückiger-Mangual is one of Tolremo’s scientific founders and experts in the field of drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training at the University of Fribourg and the ETH Zurich. Stefanie holds a Ph.D. in Molecular and Translational Biomedicine from ETH Zurich. She led the team of scientists who discovered novel molecular mechanisms that can be exploited to prevent the development of resistance to cancer therapies.
Head Business Development and Licensing at Vifor Pharma in Switzerland, President Swiss Healthcare Licensing Group and member of the European Pharma Licensing Council, Gabrielle is passionate about health & well-being. She has more than 20 years of experience in the pharmaceutical industry and held various leading positions in finance, marketing and business development. Her experience at the medical research foundation completes this profile in the field of not-for-profit organization and tech transfers. Driven by an entrepreneurial spirit, she connects quickly and aims to establish long term partnering relationships where mutual respect matters.
Co-Founder and Senior Partner
Head of Private Equity
Over 25 years experience in the Venture Capital Industry. PhD ETH Zurich in Natural Sciences and Industrial Engineering. Previously in management functions at Innoventure, Credit Suisse, Apax and Vontobel. Board member of Westmed and Reha Technology.
Seraina Gross has been working as a journalist for almost 30 years. She held positions at several newspapers including Tages-Anzeiger and Basler Zeitung as a political reporter, head of department and correspondent in Geneva. In 2015 she joined Handelszeitung, a Swiss business weekly, as a senior reporter covering the life sciences industry. Seraina studied literature and history in Zurich and Basel. In addition, she holds a Master of Advanced Studies in Marketing Management and Business Development from the University of Basel.
Chief Executive Officer and Co-Founder
Daniela Marino is CEO and co-founder of Cutiss AG, a spin-off of the University of Zurich, that was awarded as #TOP1 Swiss start-up 2020. Daniela received her MSc in Biotechnologies from the University of Milan in 2005 and her Ph.D. at the ETH Zurich in 2009. During her postdoctoral studies at the Tissue Biology Research Unit in Zurich, she specialized in tissue engineering of skin and gained expertise in project management and product development. Daniela’s professional mission is to provide a real solution to patients suffering from severe skin defects.
Biotechnology leader Germany, Switzerland, Austria
Ernst & Young
Jürg Zürcher heads EY’s Biotechnology Sector in Europe, the Middle East, India and Africa. His main focus is the life sciences sector and he is also active in the venture capital business. Jürg Zürcher provided the Swiss Federal Government with a comprehensive analysis of the state of biotechnology in Switzerland. He also supported the introduction of the first Swiss Biotech Report in March 2004.
Thomas Staffelbach is an experienced communications director, former head of communications and investor relations of several listed and private companies. Thomas is passionate about innovation and the people behind it. For almost 15 years, he has been advising biotech and pharmaceutical companies to position the medical and commercial potential of their innovations.